← Back to Search

Antibody Therapy

Convalescent donor plasma for Coronavirus

Phase 2

Waitlist Available

Led By Mila B Ortigoza, MD, PhD

Research Sponsored by NYU Langone Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 0, 1, 7, 14, 28, 90 days post randomization

Awards & highlights

Study Summary

This trial will test if anti-SARS-CoV-2 convalescent plasma can help hospitalized patients with acute respiratory symptoms requiring oxygen supplementation.

Eligible Conditions

Coronavirus
Coronavirus Infection
COVID-19

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 0, 1, 7, 14, 28, 90 days post randomization

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~0, 1, 7, 14, 28, 90 days post randomization

This trial's timeline: 3 weeks for screening, Varies for treatment, and 0, 1, 7, 14, 28, 90 days post randomization for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Score on the WHO 11-point Ordinal Scale for Clinical Improvement at 14 Days

Secondary outcome measures

Score on the WHO 11-point Ordinal Scale for Clinical Improvement at 28 Days

Other outcome measures

Changes from baseline in B lymphocyte subsets

Changes from baseline in D-dimer

Changes from baseline in T lymphocyte subsets

+7 more

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: Convalescent donor plasmaActive Control1 Intervention

Group II: Lactated ringer's solution or sterile saline solutionPlacebo Group1 Intervention

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

The University of Texas Health Science Center, HoustonOTHER

903 Previous Clinical Trials

320,036 Total Patients Enrolled

Albert Einstein College of MedicineOTHER

286 Previous Clinical Trials

11,856,040 Total Patients Enrolled

The University of Texas Health Science Center at TylerOTHER

14 Previous Clinical Trials

24,747 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this experiment recruiting participants presently?

"This clinical trial, which debuted on April 17th 2020 and was last modified on March 30 2022, is no longer recruiting. Nevertheless, 1049 different trials are presently enrolling patients."

Answered by AI

Are there various medical centers running this research within the city limits?

"Currently, 9 clinical trial sites are conducting this research. These locations include New Haven, Tyler and Houston amongst others. It might be wise to select a nearby location in order to limit travel needs should you wish to join the study."

Answered by AI

Could you provide an appraisal of the hazards associated with convalescent donor plasma?

"Our team at Power estimates that convalescent donor plasma is moderately safe with a safety rating of 2. Even though there may be some evidence for its security, no data has been gathered to back up its effectiveness yet."

Answered by AI